

**Infectious Disease Therapeutics Market Assessment, By Mode of Treatment [Vaccines, Drugs], By Infection Type [Viral Infection, Bacterial Infection, Fungal Infection, Parasitic Infection, Others], By Route of Administration [Oral, Parenteral, Others], By Diagnostic Technique [Immunodiagnosics, Polymerase Chain Reaction, Clinical Microbiology, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing, Next Generation Sequencing, DNA Microarray, Others], By End-user [Hospitals, Diagnostic Centres, Retail Pharmacy, Others], By Region, Opportunities and Forecast, 2017-2031F**

Market Report | 2024-04-19 | 242 pages | Market Xcel - Markets and Data

**AVAILABLE LICENSES:**

- Single User License \$4500.00
- Muti-User/Corporate Licence \$5700.00
- Custom Research License \$8200.00

**Report description:**

Global infectious disease therapeutics market is projected to witness a CAGR of 5.76% during the forecast period 2024-2031, growing from USD 108.09 billion in 2023 to USD 169.15 billion in 2031. Infectious diseases have a significant impact on the global healthcare market, leading to economic, social, and health-related consequences. Tuberculosis accounted for the second highest deaths from infectious disease in 2022 after COVID-19. COVID-19, tuberculosis, HIV/AIDS, and malaria accounted for 1.24 million, 1.13 million, 0.63 million, and 0.62 million deaths respectively. The global healthcare industry is under significant pressure due to infectious diseases, which are caused by various infectious agents such as viruses, viroids, and bacteria. Although advanced diagnosis and treatment options, as well as improvements in hygiene, vaccination, and antimicrobial therapy, have reduced the number of deaths caused by infectious diseases, the rise and re-occurrence of infectious diseases continue to affect global health

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

outcome. The infectious disease therapeutics market is expected to grow significantly over the forecast period due to rising infectious disease occurrences, increased awareness about early infectious disease diagnosis, and increased research and funding activities by various private and government organizations.

For instance, WHO launched a global network to detect and prevent infectious disease threats in 2023. Not only does this initiative provide a platform to connect countries and regions, but it also improves the system for analyzing and collecting samples from around the globe, which will help and improve the public healthcare sector in decision-making and welfare.

#### Increasing Prevalence and Mortality Rate of Infectious Diseases

The increasing prevalence of infectious diseases is expected to drive the sales of infectious disease therapeutics in developing nations. Furthermore, significant investments in health research and life sciences in emerging countries are facilitating the adoption of advanced technologies, thereby promoting the diagnosis and treatment of infectious diseases. Morbidity and mortality are mainly caused due to infectious diseases. Such diseases are the cause of more than 33% or 52 million annual deaths, globally. Nearly half of the global population is at risk of recurring infectious diseases.

Countries, such as India, South Korea, Brazil, and Mexico, have a high burden of infectious diseases like Hepatitis, HAI, HIV, and influenza. As a result, medical device companies are increasing investments and manufacturing capacities in these countries to meet the demand for diagnostic devices and instruments over the forecast period.

#### Viral Therapeutics are Dominating the Market

In 2022, viral therapeutics held the second-largest market share in the infectious disease therapeutics sector. The significant share held by this segment is attributed to the growing prevalence of viral diseases like hepatitis and HIV, the increasing number of clinical trials for new drug launches, and initiatives aimed at enhancing drug adoption. Hepatitis and human papillomavirus patients are increasing at a rapid rate globally. Due to the rapid increase in the prevalence and incidence of infectious diseases, medical device manufacturers are prioritizing innovation and manufacturing capacities.

The World Health Organization's (WHO) Global Health Sector Strategy on viral hepatitis aims to test and treat a large proportion of individuals with HBV and HCV by 2030. In January 2023, the Serum Institute of India launched 'CERVAVAC,' the first Quadrivalent Human Papillomavirus vaccine made in India, in collaboration with DBT, BIRAC, and the Bill and Melinda Gates Foundation. This vaccine is India's first indigenously developed vaccine for the prevention of cervical cancer. This vaccine is affordable and cost effective and the government of India has taken initiatives to make it accessible for everyone in the country.

#### Government Initiatives

Governments around the globe have been actively engaged in fostering advancements within the infectious disease therapeutics market through various initiatives. These efforts aim to address emerging health challenges and ensure preparedness for infectious outbreaks. Governments often allocate substantial funding for research and development, supporting pharmaceutical companies and academic institutions with their objective of developing innovative therapeutics. Additionally, regulatory bodies play a crucial role in streamlining the approval process to expedite the availability of new treatments. For instance, in India, the Infectious Disease Biology Program aims to provide solutions to infectious diseases of global concern such as HIV/AIDS, tuberculosis, and vector borne diseases, along with emerging or re-emerging threats like influenza, Japanese Encephalitis, and antibiotic-resistant microbes in terms of therapeutics, diagnostics, and preventive measures. The Program supports R&D projects to achieve the Sustainable Development Goals Target to combat various water-borne diseases, communicable diseases, and hepatitis and end the epidemics of viral diseases like AIDS, TB, and malaria by the year 2030.

#### Dominance of Molecular Diagnostic Techniques, Especially PCR

Nucleic Acid amplification tests, PCR, are a few molecular diagnostic techniques that are going to be more popular in the coming frame of time. PCR is the most widely used nucleic acid amplification method for pathogen detection and has become an important tool in the early diagnosis of infectious diseases, bacterial infections, GI infections, and sexually transmitted diseases. Thermo Fisher launched real-time PCR kits for the detection of infectious diseases in India in February 2023. The TaqPath PCR kits provide assurance and consistency for the creation and examination of diagnostic tests for infectious diseases. Genetic risk factor identification, therapy response monitoring, and disease screening are a few patient care practices that can be now carried out using the TaqPath PCR kits developed by Thermo Fisher.

#### North America Dominates Infectious Disease Therapeutics Market

North America is dominating the infectious diseases therapeutics market due to the increasing prevalence of infectious diseases,

improving healthcare infrastructure, the presence of key market players, and rising awareness programs. Government initiatives and their effort towards providing the country with adequate infrastructure and facilities, such as trained professionals, high-end medical devices, and drugs, are creating lucrative market opportunities in the region. Other factors accelerating the market demand in North America includes the growing prevalence of such diseases, favorable reimbursement scenarios, the presence of numerous manufacturers in the U.S., and an increasing number of clinical trials for developing new treatment drugs and devices. According to the Centers for Disease Control and Prevention, in the United States., influenza and pneumonia caused 41,917 deaths in 2022.

#### Future Market Scenario (2024 - 2031F)

The future market scenario for treatments for infectious diseases is expected to be dynamic, driven by continued technological development and a greater emphasis on preventive measures. More individualized and efficient treatments are expected by the ongoing development of precision medicine, which is made possible by advancements in genomics and personalized therapies. Novel treatments for infectious diseases are being made possible by developments in immunotherapy and antiviral drugs, which are changing the market landscape. The COVID-19 pandemic has expedited the development, production, and distribution of vaccines, enabling a more responsive approach to newly emerging infectious diseases.

#### Key Players Landscape and Outlook

The global market for infectious disease therapeutics is fiercely competitive and somewhat fragmented. To stay ahead, major industry players continuously implement various growth strategies such as innovations, mergers, acquisitions, collaborations, and partnerships. Additionally, they focus on research and development to provide the most effective and economical solutions. Most prominent players of this market, such as Pfizer Inc, Gilead Sciences Inc, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim GmbH, Bayer AG, Janssen Pharmaceutical, GSK Plc, AbbVie Inc, Merck & Co Inc, and Astellas Pharma Inc., are the ones mostly bringing new innovations and robust technology in the market.

In January 2023, Thermo Fisher Scientific Inc. (US) introduced the CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit. This kit is designed to detect genomic mutations in HIV-1 viral ribonucleic acid extracted from plasma or dried blood spots, specifically analyzing mutations in the protease, reverse transcriptase, and integrase regions of the pol gene. Roche introduced the Elecsys HCV Duo in July 2022. This immunoassay enables the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.

May & Baker Nigeria Plc launched Artelum Combo, a new drug to combat malaria parasites across Nigeria in March 2022. The medicine is a unique combination of Artemeter Lumefantrine and Paracetamol, providing complete malaria therapy in a single package.

#### Table of Contents:

- 1.□Research Methodology
- 2.□Project Scope & Definitions
- 3.□Executive Summary
- 4.□Global Infectious Disease Therapeutics Market Outlook, 2017-2031F
  - 4.1.□Market Size & Forecast
    - 4.1.1.□Value
    - 4.1.2.□Volume
  - 4.2.□By Mode of Treatment
    - 4.2.1.□Vaccines
    - 4.2.2.□Drugs
  - 4.3.□By Infection Type
    - 4.3.1.□Viral Infection
    - 4.3.2.□Bacterial Infection
    - 4.3.3.□Fungal Infection
    - 4.3.4.□Parasitic Infection
    - 4.3.5.□Others

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.4.□By Route of Administration
  - 4.4.1.□Oral
  - 4.4.2.□Parenteral
    - 4.4.2.1.□Subcutaneous
    - 4.4.2.2.□Intravenous
    - 4.4.2.3.□Intradermal
    - 4.4.2.4.□Intramuscular
  - 4.4.3.□Others
- 4.5.□By Diagnostic Technique
  - 4.5.1.□Immunodiagnosics
  - 4.5.2.□Polymerase Chain Reaction
  - 4.5.3.□Clinical Microbiology
  - 4.5.4.□Isothermal Nucleic Acid Amplification Technology
  - 4.5.5.□DNA Sequencing
  - 4.5.6.□Next Generation Sequencing
  - 4.5.7.□DNA Microarray
  - 4.5.8.□Others
- 4.6.□By End-user
  - 4.6.1.□Hospitals
  - 4.6.2.□Diagnostic Centres
  - 4.6.3.□Retail Pharmacies
  - 4.6.4.□Others
- 4.7.□By Region
  - 4.7.1.□North America
  - 4.7.2.□Europe
  - 4.7.3.□South America
  - 4.7.4.□Asia-Pacific
  - 4.7.5.□Middle East and Africa
- 4.8.□By Company Market Share (%), 2023
- 5.□Global Infectious Disease Therapeutics Market Outlook, By Region, 2017-2031F
  - 5.1.□North America\*
    - 5.1.1.□Market Size & Forecast
      - 5.1.1.1.□Value
      - 5.1.1.2.□Volume
    - 5.1.2.□By Mode of Treatment
      - 5.1.2.1.□Vaccines
      - 5.1.2.2.□Drugs
    - 5.1.3.□By Infection Type
      - 5.1.3.1.□Viral Infection
      - 5.1.3.2.□Bacterial Infection
      - 5.1.3.3.□Fungal Infection
      - 5.1.3.4.□Parasitic Infection
      - 5.1.3.5.□Others
    - 5.1.4.□By Route of Administration
      - 5.1.4.1.1.□Oral
      - 5.1.4.1.2.□Parenteral
        - 5.1.4.1.2.1.□Subcutaneous

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.1.4.1.2.2.□Intravenous
- 5.1.4.1.2.3.□Intradermal
- 5.1.4.1.2.4.□Intramuscular
- 5.1.4.1.3.□Others
- 5.1.5.□By Diagnostic Technique
- 5.1.5.1.□Immunodiagnostics
- 5.1.5.2.□Polymerase Chain Reaction
- 5.1.5.3.□Clinical Microbiology
- 5.1.5.4.□Isothermal Nucleic Acid Amplification Technology
- 5.1.5.5.□DNA Sequencing
- 5.1.5.6.□Next Generation Sequencing
- 5.1.5.7.□DNA Microarray
- 5.1.5.8.□Others
- 5.1.6.□By End-user
- 5.1.6.1.□Hospitals
- 5.1.6.2.□Diagnostic Centres
- 5.1.6.3.□Retail Pharmacies
- 5.1.6.4.□Others
- 5.1.7.□ United States\*
- 5.1.7.1.□Market Size & Forecast
- 5.1.7.1.1.□By Value
- 5.1.7.1.2.□By Volume
- 5.1.7.2.□By Mode of Treatment
- 5.1.7.2.1.□Vaccines
- 5.1.7.2.2.□Drugs
- 5.1.7.3.□By Infection Type
- 5.1.7.3.1.□Viral Infection
- 5.1.7.3.2.□Bacterial Infection
- 5.1.7.3.3.□Fungal Infection
- 5.1.7.3.4.□Parasitic Infection
- 5.1.7.3.5.□Others
- 5.1.7.4.□By Route of Administration
- 5.1.7.4.1.1.□Oral
- 5.1.7.4.1.2.□Parenteral
- 5.1.7.4.1.2.1.□Subcutaneous
- 5.1.7.4.1.2.2.□Intravenous
- 5.1.7.4.1.2.3.□Intradermal
- 5.1.7.4.1.2.4.□Intramuscular
- 5.1.7.4.1.3.□Others
- 5.1.7.5.□By Diagnostic Technique
- 5.1.7.5.1.□Immunodiagnostics
- 5.1.7.5.2.□Polymerase Chain Reaction
- 5.1.7.5.3.□Clinical Microbiology
- 5.1.7.5.4.□Isothermal Nucleic Acid Amplification Technology
- 5.1.7.5.5.□DNA Sequencing
- 5.1.7.5.6.□Next Generation Sequencing
- 5.1.7.5.7.□DNA Microarray

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.1.7.5.8.□Others
- 5.1.7.6.□By End-user
- 5.1.7.6.1.□Hospitals
- 5.1.7.6.2.□Diagnostic Centres
- 5.1.7.6.3.□Retail Pharmacies
- 5.1.7.6.4.□Others
- 5.1.8.□Canada
- 5.1.9.□Mexico
- \*All segments will be provided for all regions and countries covered
- 5.2.□Europe
- 5.2.1.□Germany
- 5.2.2.□France
- 5.2.3.□Italy
- 5.2.4.□United Kingdom
- 5.2.5.□Russia
- 5.2.6.□Spain
- 5.2.7.□Others
- 5.3.□South America
- 5.3.1.□Brazil
- 5.3.2.□Argentina
- 5.4.□Asia-Pacific
- 5.4.1.□India
- 5.4.2.□China
- 5.4.3.□Japan
- 5.4.4.□Australia
- 5.4.5.□South Korea
- 5.4.6.□Others
- 5.5.□Middle East & Africa
- 5.5.1.□Saudi Arabia
- 5.5.2.□UAE
- 5.5.3.□South Africa
- 6.□Market Mapping, 2023
- 6.1.□By Mode of Treatment
- 6.2.□By Infection Type
- 6.3.□By Route of Administration
- 6.4.□By Diagnostic Technique
- 6.5.□By End-user
- 6.6.□By Region
- 7.□Macro Environment and Industry Structure
- 7.1.□Supply Demand Analysis
- 7.2.□Import Export Analysis
- 7.3.□Value Chain Analysis
- 7.4.□PESTEL Analysis
- 7.4.1.□Political Factors
- 7.4.2.□Economic System
- 7.4.3.□Social Implications
- 7.4.4.□Technological Advancements

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.5.□Environmental Impacts
  - 7.4.6.□Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  - 7.5.□Porter's Five Forces Analysis
    - 7.5.1.□Supplier Power
    - 7.5.2.□Buyer Power
    - 7.5.3.□Substitution Threat
    - 7.5.4.□Threat from New Entrant
    - 7.5.5.□Competitive Rivalry
  - 8.□Market Dynamics
    - 8.1.□Growth Drivers
    - 8.2.□Growth Inhibitors (Challenges and Restraints)
  - 9.□Regulatory Framework and Innovation
    - 9.1.□Clinical Trials
    - 9.2.□Patent Landscape
    - 9.3.□Regulatory Approvals
    - 9.4.□Innovations/Emerging Technologies
  - 10.□Key Players Landscape
    - 10.1.□Competition Matrix of Top Five Market Leaders
    - 10.2.□Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
    - 10.3.□Mergers and Acquisitions/Joint Ventures (If Applicable)
    - 10.4.□SWOT Analysis (For Five Market Players)
    - 10.5.□Patent Analysis (If Applicable)
  - 11.□Pricing Analysis
  - 12.□Case Studies
  - 13.□Key Players Outlook
    - 13.1.□AbbVie Inc.
      - 13.1.1.□Company Details
      - 13.1.2.□Key Management Personnel
      - 13.1.3.□Products & Services
      - 13.1.4.□Financials (As reported)
      - 13.1.5.□Key Market Focus & Geographical Presence
      - 13.1.6.□Recent Developments
    - 13.2.□Boehringer Ingelheim GmbH
    - 13.3.□F Hoffmann-La Roche, Ltd
    - 13.4.□Bayer AG
    - 13.5.□GlaxoSmithKline plc.
    - 13.6.□Pfizer Inc.
    - 13.7.□Janssen Pharmaceutical (Johnson & Johnson)
    - 13.8.□Merck & Co., Inc.
    - 13.9.□Novartis AG
    - 13.10.□Moderna, Inc.
    - 13.11.□Eli Lilly & Co
    - 13.12.□Novo Nordisk, Inc.
    - 13.13.□Applied Molecular Genetics Inc.
- \*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
- 14.□Strategic Recommendations

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com





**Infectious Disease Therapeutics Market Assessment, By Mode of Treatment [Vaccines, Drugs], By Infection Type [Viral Infection, Bacterial Infection, Fungal Infection, Parasitic Infection, Others], By Route of Administration [Oral, Parenteral, Others], By Diagnostic Technique [Immunodiagnosics, Polymerase Chain Reaction, Clinical Microbiology, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing, Next Generation Sequencing, DNA Microarray, Others], By End-user [Hospitals, Diagnostic Centres, Retail Pharmacy, Others], By Region, Opportunities and Forecast, 2017-2031F**

Market Report | 2024-04-19 | 242 pages | Market Xcel - Markets and Data

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4500.00
	Muti-User/Corporate Licence	\$5700.00
	Custom Research License	\$8200.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)